Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced solid tumors (excluding SCLC and retinoblastoma) or follicular of diffuse large cell non-Hodgkin's lymphoma, histologically or cytologically proven at diagnosis which is refractory to or intolerant of established therapy know to provide clinical benefit for their condition; tumors must express Rb~* Adequate blood cell counts, kidney function and liver function and and ECOG score of 0, 1, or 2.~* Patients may have to have tumor biopsy before and after treatment.~Exclusion Criteria:~* Prior stem cell or bone marrow transplant~* Uncontrolled infection, unstable or sever intercurrent medical condition, or current drug or alcohol abuse~* Active or unstable cardiac disease or history of heart attack within 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PD-0332991 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).